Compare LFUS & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LFUS | BIO |
|---|---|---|
| Founded | 1927 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Laboratory Analytical Instruments |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 10.1B |
| IPO Year | 1996 | 1994 |
| Metric | LFUS | BIO |
|---|---|---|
| Price | $413.82 | $363.46 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $496.25 | $328.33 |
| AVG Volume (30 Days) | 172.2K | ★ 249.4K |
| Earning Date | 10-28-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | ★ 2.96 | N/A |
| Revenue | $757,853,000.00 | ★ $2,583,200,000.00 |
| Revenue This Year | $23.70 | N/A |
| Revenue Next Year | $10.07 | $2.13 |
| P/E Ratio | $139.80 | ★ N/A |
| Revenue Growth | N/A | ★ 0.65 |
| 52 Week Low | $233.36 | $236.73 |
| 52 Week High | $500.57 | $396.23 |
| Indicator | LFUS | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.68 | 45.57 |
| Support Level | $389.23 | $358.85 |
| Resistance Level | $428.88 | $391.87 |
| Average True Range (ATR) | 11.72 | 12.72 |
| MACD | -2.09 | -2.02 |
| Stochastic Oscillator | 13.18 | 29.96 |
Littelfuse is a supplier of circuit protection products (such as fuses and relays) for the transportation, industrial, telecommunications, and consumer electronics end markets. Littelfuse also holds a minority power semiconductor business, primarily serving high-voltage industrial applications. Littelfuse sells globally across both distribution and direct channels, and organizes its business into the three segments of electronics, transportation, and industrial. Littelfuse is a serial acquirer of smaller, bolt-on adjacent firms.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.